Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$4.46 USD
+0.15 (3.48%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.46 USD
+0.15 (3.48%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $4.46 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
New Strong Buy Stocks for May 9th
by Zacks Equity Research
SBGI, AQST, PLTK, GTX and LRMR have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2023
Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 210% and 9.48%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -9.52% and 7.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Assertio (ASRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Aquestive Therapeutics (AQST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 23.33% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
RedHill (RDHL) Up on Orphan Drug Tag for NTM Disease Drug
by Zacks Equity Research
RedHill's (RDHL) RHB-204 gets Orphan Drug designation from the European Commission for the treatment of nontuberculous mycobacteria (NTM) disease
Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings and revenues fall shy of estimates in the second quarter of 2022.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 12.20% and 32.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the international markets.
Verve (VERV) Up on Gene Editing Collaboration With Vertex
by Zacks Equity Research
Verve Therapeutics (VERV) enters into a four-year collaboration with Vertex Therapeutics to develop a gene-editing program targeted at liver disease for an upfront payment of $60 million.
Marinus (MRNS) to Sell Rare Disease PRV to Novo Nordisk
by Zacks Equity Research
Marinus Pharmaceuticals (MRNS) agrees to sell its Rare Pediatric Disease Priority Review Voicer (RPV) to Novo Nordisk for $110 million.
Vaxcyte (PCVX) Completes Enrollment in Pneumococcal Disease Study
by Zacks Equity Research
Vaxcyte (PCVX) enrolls the last patient in the phase II portion of phase I/HH study, evaluating VAX-24 for preventing invasive pneumococcal disease and pneumonia in healthy adults.
Rhythm (RYTM) Surges on Upbeat Data on Lead Product Candidate
by Zacks Equity Research
Rhythm Pharmaceuticals (RYTM) reports favorable data from a mid-stage study evaluating the efficacy of setmelanotide, its MC4R agonist, for treating hypothalamic obesity.
Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study
by Zacks Equity Research
Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.
Intercept (ICPT) Reports Positive Data From NASH Study on OCA
by Zacks Equity Research
Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.
Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt
by Zacks Equity Research
Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.
Roche's (RHHBY) Lunsumio Application Gets Priority Review
by Zacks Equity Research
Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory follicular lymphoma has been granted priority review in the United States.
ChemoCentryx's (CCXI) Tavneos Aids Growth, Overdependence a Woe
by Zacks Equity Research
ChemoCentryx (CCXI) has only one product approved for sale in its portfolio, Tavneos. Nevertheless, it is progressing well with the clinical development of its pipeline candidates.
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 28.89% and 25.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -2.70% and 12.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?